Careers  |  Sign In  |  Register  |   Twitter

Dual Diabetes Drug Recommended for Approval

A two in one diabetes drug, created by Danish drug maker Novo Nordisk, has been recommended for approval by the European Union, a Reuters article reports. Clinical trials of the drug, Xultophy, have proven that simultaneous consumption of liraglutide (Victoza) and degludec — the components of Xultophy — promotes weight loss and lowers  blood sugar more than if each drug were taken individually. For a market of 382 million diabetics worldwide, the disease draws significant interest from pharmaceutical companies.

Read the article published by Reuters.